| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
DE:BAYN
Bayer
|
Oct 30, 2026 | HOLD |
Strong Buy
+8.7% avg upside
31 analysts
|
$46.00
8.34% Downside
|
+11.1% | Β· |
|
FR:SAN
Sanofi
|
Oct 30, 2026 | BUY |
Buy
+21.3% avg upside
30 analysts
|
$100.00
25.43% Upside
|
+3.9% | Β· |
|
GSK
GlaxoSmithKline
|
Oct 28, 2026 | HOLD |
Hold
-14.7% avg upside
20 analysts
|
$55.90
12.87% Upside
|
+4.2% | Β· |
|
GB:GSK
GlaxoSmithKline
|
Oct 28, 2026 | BUY |
Hold
+5.2% avg upside
26 analysts
|
$2500.00
34.75% Upside
|
+3.2% | Β· |
|
CH:NOVN
Novartis AG
|
Oct 27, 2026 | HOLD |
Buy
-15.0% avg upside
32 analysts
|
$110.00
17.78% Downside
|
+3.0% | Β· |
|
GB:AZN
AstraZeneca
|
Oct 27, 2026 | BUY |
Strong Buy
+7.8% avg upside
28 analysts
|
$17500.00
25.36% Upside
|
+8.6% | Β· |
|
CH:ROP
Roche Holding AG
|
Oct 23, 2026 | SELL |
Buy
-12.1% avg upside
24 analysts
|
$250.00
37.95% Downside
|
+1.6% | Β· |
|
DE:SRT3
Sartorius
|
Aug 21, 2023 | BUY |
Strong Buy
-0.2% avg upside
19 analysts
|
$470.00
61.16% Upside
|
-31.2% | Β· |
|
DE:MRK
Merck KGaA
|
Aug 04, 2023 | BUY |
Buy
-7.2% avg upside
34 analysts
|
$208.00
37.53% Upside
|
+3.2% | Β· |
|
FR:IPN
Ipsen
|
Jun 30, 2023 | HOLD |
Hold
-20.5% avg upside
17 analysts
|
$113.00
28.36% Downside
|
+5.7% | Β· |
|
FR:DIM
Sartorius Stedim Biotech
|
Jun 19, 2023 | BUY |
Strong Buy
+19.8% avg upside
12 analysts
|
$390.00
74.62% Upside
|
-34.1% | Β· |
|
GB:SHEL
Shell (UK)
|
Oct 10, 2022 | BUY |
Strong Buy
+316.4% avg upside
27 analysts
|
$2650.00
34.35% Downside
|
+15.8% | Β· |
|
NVO
Novo Nordisk
|
Jun 28, 2022 | SELL |
Buy
+188.3% avg upside
26 analysts
|
β | -46.7% | Β· |
|
DE:SRT
Sartorius
|
Feb 28, 2022 | SELL |
Strong Buy
+64.4% avg upside
5 analysts
|
$400.00
74.64% Upside
|
+10.8% | Β· |
|
DE:FME
Fresenius Medical Care AG & Co. KGaA
|
Nov 04, 2021 | BUY |
Hold
+22.7% avg upside
24 analysts
|
$80.00
98.10% Upside
|
-52.2% | Β· |
|
DE:FRE
Fresenius SE & Co. KGaA
|
Nov 02, 2021 | HOLD |
Strong Buy
+8.4% avg upside
21 analysts
|
$45.00
5.90% Downside
|
-40.3% | Β· |
|
CH:ALC
Alcon
|
Aug 23, 2021 | BUY |
Strong Buy
+19.4% avg upside
36 analysts
|
$85.00
43.81% Upside
|
-9.4% | Β· |
|
SNY
Sanofi
|
May 12, 2016 | BUY |
Strong Buy
+64.5% avg upside
20 analysts
|
β | +29.5% | Β· |
|
NVS
Novartis
|
Apr 22, 2016 | HOLD |
Hold
-16.1% avg upside
24 analysts
|
β | -0.5% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.